Focus sur les CAR-T cells, Dre Sarah Morin, Dr Federico Simonetta, 15.09.20

1. Focus sur les CAR-T cells : une nouvelle génération de traitements pour les hémopathies malignes
2. Conflicts of Interest
3. Chimeric Antigen Receptor (CAR) T cells
4. Chimeric Antigen Receptor (CAR) T cells history
5. Approved CAR T cells
6. CD19 expression
7. Approved CAR T cells
8. CAR T cell manufacturing
9. Approved CAR T cells
10. Approved CAR T cells
11. Approved CAR T cells
12. Approved CAR T cells
13. The unmet clinical need in R/R DLBCL SCHOLAR 1
14. Pivotal Clinical Trials
15. Real-world experience - US experience
16. Real-world experience - French experience
17. CAR T cells in DLBCL - Next future
18. Approved CAR T cells
19. B-ALL outcomes
20. Pivotal Clinical Trial
21. Real-world experience - US experience
22. Real-world experience - French experience
23. Management of CAR-T cell toxicties is more difficult in older patients
24. Fractionnated tisa-cell in adult B-ALL
25. Fractionnated tisa-cell in adult B-ALL
26. Fractionnated tisa-cell in adult B-ALL
27. Fractionnated tisa-cell in adult B-ALL
28. Risk of relapse after achieving MRD-negative response
29. Should we transplant B-ALL patients post CAR-T ?
30. Patient Journey
31. Patient Journey
32. Patient Journey
33. Patient Journey
34. Patient Journey
35. Patient Journey
36. Patient Journey
37. Patient Journey
38. Complications
39. Complications
40. Complications
41. Complications
42. Patient Journey
43. Complications
44. Conclusions
45. Conclusions
46. Conclusions
47. Conclusions
48. Conclusions
49. Acknowledgements

FINISH

SUBMIT

Title